HCM
GALT icon

Highbridge Capital Management’s Galectin Therapeutics GALT Stock Holding History

Highbridge Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30,973
Closed -$474K – 1140
2014
Q1 		$474K Buy
+30,973
New +$441K 0.01% 718

Other funds holding GALT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Highbridge Capital Management's GALT Position: Q2 2014 in Review

Highbridge Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2014, closing a stake of 30,973 shares — an estimated $474K sold.

Highbridge Capital Management first reported a position in GALT in Q1 2014 and held it in 1 quarter. The position peaked at $474K in Q1 2014. 65 funds tracked by Wall St. Rank hold GALT as of Q2 2014.

  • Highbridge Capital Management reported no remaining Galectin Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Highbridge Capital Management sold 30,973 Galectin Therapeutics shares in Q2 2014, an estimated $474K.
  • Highbridge Capital Management first reported a position in Galectin Therapeutics in Q1 2014 and held it in 1 quarter.
  • Highbridge Capital Management's Galectin Therapeutics position peaked at $474K in Q1 2014.
  • 65 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2014.

Based on Highbridge Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.